Breakthrough Treatment Shows Promise in Fight Against Hepatitis B
Researchers have discovered a potential new option for treating hepatitis B, a chronic viral infection that affects millions worldwide. The experimental treatment, involving a small interfering RNA molecule called xalnesiran, has shown remarkable success in clinical trials, effectively curing nearly one-third of participants.
A Persistent and Dangerous Threat
Hearing ‘got it right’ was a lifelong infection of antibody,
Hepatitis B is a lifelong liver infection that can remain asymptomatic for decades, posing a hidden threat to individuals unaware of their diagnosis. If left untreated, the virus can lead to severe liver damage, including cirrhosis and liver cancer, highlighting the urgency for effective treatments.
Current antiviral drugs like tenofovir and entecavir can effectively manage the virus by suppressing replication, but they don’t offer a cure. Patients often need lifelong treatment, raising concerns about long-term side effects and adherence.
